Trials / Completed
CompletedNCT01267812
Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation
A Phase II Study of Weekly Maintenance Bortezomib and Rituximab in Mantle Cell Lymphoma Post Autologous Hematopoietic Cell Transplantation
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- City of Hope Medical Center · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving bortezomib together with rituximab may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bortezomib and rituximab together works in treating patients with mantle cell lymphoma who have previously undergone stem cell transplantation
Detailed description
PRIMARY OBJECTIVES: I. To evaluate the two year disease free survival in mantle cell lymphoma (MCL) patients treated with bortezomib + rituximab after hematopoietic stem cell transplantation (HSCT). SECONDARY OBJECTIVES: I. To evaluate the toxicity profile, safety, overall survival, time to treatment failure, remission duration, and biological markers of mantle cell lymphoma patients treated with bortezomib + rituximab after autologous hematopoietic stem cell transplantation. OUTLINE: Patients receive bortezomib subcutaneously (SC) or intravenously (IV) over 3-5 seconds and rituximab IV on days 1, 8, 15, and 22. Treatment with bortezomib repeats every 3 months for up to 8 courses and treatment with rituximab repeats every 6 months for up to 4 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 6 months for 3 years.
Conditions
- Contiguous Stage II Mantle Cell Lymphoma
- Noncontiguous Stage II Mantle Cell Lymphoma
- Recurrent Mantle Cell Lymphoma
- Stage I Mantle Cell Lymphoma
- Stage III Mantle Cell Lymphoma
- Stage IV Mantle Cell Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bortezomib | Given SC or IV |
| BIOLOGICAL | rituximab | Given IV |
| OTHER | laboratory biomarker analysis | Correlative studies |
| OTHER | immunohistochemistry staining method | Correlative studies |
| GENETIC | RNA analysis | Correlative studies |
| GENETIC | gene expression analysis | Correlative studies |
| GENETIC | DNA analysis | Correlative studies |
| OTHER | pharmacological study | Correlative studies |
| OTHER | pharmacogenomic studies | Correlative studies |
| OTHER | Questionnaire Administration |
Timeline
- Start date
- 2011-10-03
- Primary completion
- 2020-11-02
- Completion
- 2020-11-02
- First posted
- 2010-12-29
- Last updated
- 2023-07-27
- Results posted
- 2022-02-04
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01267812. Inclusion in this directory is not an endorsement.